Management of Patients With NSTE-ACS: A Comparison of the Recent AHA/ACC and ESC Guidelines

Journal of the American College of Cardiology

Volumn 68, Issue 3, 2016, Pages 313-321

  Rodriguez, Fatima ^a   Mahaffey, Kenneth W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute coronary syndrome; anticoagulants; antiplatelet; quality of care; risk assessment

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CANGRELOR; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; PRASUGREL; TICAGRELOR; TROPONIN; ANTITHROMBOCYTIC AGENT;

ANTICOAGULANT THERAPY; CARDIOVASCULAR DISEASE; CLINICAL PROTOCOL; COMPARATIVE STUDY; CORONARY ANGIOGRAPHY; DIABETES MELLITUS; HUMAN; MEDICAL SOCIETY; MORBIDITY; MORTALITY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RADIAL ARTERY; REVIEW; RISK ASSESSMENT; VASCULAR ACCESS; ACUTE CORONARY SYNDROME; CARDIOLOGY; ELECTROCARDIOGRAPHY; EUROPE; PROCEDURES; UNITED STATES;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; CARDIOLOGY; ELECTROCARDIOGRAPHY; EUROPE; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84979955430     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.03.599     Document Type: Review

References (67)

1. 1 Amsterdam, E.A., Wenger, N.K., Brindis, R.G., et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64 (2014), e139–e228.
2. 2 Roffi, M., Patrono, C., Collet, J.P., et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 37 (2016), 267–315.
3. 3 American College of Cardiology Foundation and the American Heart Association Inc. Methodology Manual and Policies from the ACCF/AHA Task Force on Practice Guidelines. 2010. Available at: https://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf. Accessed May 9, 2016.
4. 4 Committee for Practice Guidelines (CPG) of the European Society of Cardiology (ESC). Recommendations for guideline production. 2012. Available at: https://www.escardio.org/static_file/Escardio/Guidelines/about/ESC_Guidelines_for_Guidelines_Update_2012_for_web.pdf. Accessed May 9, 2016.
5. 5 Reichlin, T., Hochholzer, W., Bassetti, S., et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 361 (2009), 858–867.
6. 6 Keller, T., Zeller, T., Peetz, D., et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 361 (2009), 868–877.
7. 7 Haaf, P., Drexler, B., Reichlin, T., et al. High-sensitivity cardiac troponin in the distinction of acute myocardial infarction from acute cardiac noncoronary artery disease. Circulation 126 (2012), 31–40.
8. 8 Keller, T., Zeller, T., Ojeda, F., et al. Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. JAMA 306 (2011), 2684–2693.
9. 9 Maisel, A., Mueller, C., Neath, S.X., et al. Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction). J Am Coll Cardiol 62 (2013), 150–160.
10. 10 Möckel, M., Searle, J., Hamm, C., et al. Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study. Eur Heart J 36 (2015), 369–376.
11. 11 Raskovalova, T., Twerenbold, R., Collinson, P.O., et al. Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out of myocardial infarction: a systematic review and meta-analysis. Eur Heart J Acute Cardiovasc Care 3 (2014), 18–27.
12. 12 Fox, K.A., Dabbous, O.H., Goldberg, R.J., et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ, 333, 2006, 1091.
13. 13 Fox, K.A., Eagle, K.A., Gore, J.M., et al., for the GRACE and GRACE 2 Investigators. The Global Registry of Acute Coronary Events, 1999 to 2009—GRACE. Heart 96 (2010), 1095–1101.
14. 14 Antman, E.M., Cohen, M., Bernink, P.J., et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 284 (2000), 835–842.
15. 15 Hamm, C.W., Bassand, J.P., Agewall, S., et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 32 (2011), 2999–3054.
16. 16 Aragam, K.G., Tamhane, U.U., Kline-Rogers, E., et al. Does simplicity compromise accuracy in ACS risk prediction? A retrospective analysis of the TIMI and GRACE risk scores. PLoS One, 4, 2009, e7947.
17. 17 Amsterdam, E.A., Kirk, J.D., Diercks, D.B., et al. Immediate exercise testing to evaluate low-risk patients presenting to the emergency department with chest pain. J Am Coll Cardiol 40 (2002), 251–256.
18. 18 Nabi, F., Chang, S.M., Xu, J., et al. Assessing risk in acute chest pain: the value of stress myocardial perfusion imaging in patients admitted through the emergency department. J Nucl Cardiol 19 (2012), 233–243.
19. 19 Shah, B.N., Balaji, G., Alhajiri, A., et al. Incremental diagnostic and prognostic value of contemporary stress echocardiography in a chest pain unit: mortality and morbidity outcomes from a real-world setting. Circ Cardiovasc Imaging 6 (2013), 202–209.
20. 20 Hamon, M., Pristipino, C., Di Mario, C., et al. Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care and Thrombosis of the European Society of Cardiology. EuroIntervention 8 (2013), 1242–1251.
21. 21 Jolly, S.S., Yusuf, S., Cairns, J., et al., for the RIVAL trial group. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 377 (2011), 1409–1420.
22. 22 Rao, S.V., Hess, C.N., Barham, B., et al. A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. J Am Coll Cardiol Intv 7 (2014), 857–867.
23. 23 Lubsen, J., Tijssen, J.G., Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT). Am J Cardiol 60 (1987), 18A–25A.
24. 24 CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 363 (2010), 930–942.
25. 25 Wiviott, S.D., Braunwald, E., McCabe, C.H., et al., for the TRITON–TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007), 2001–2015.
26. 26 Roe, M.T., Armstrong, P.W., Fox, K.A., et al., TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 367 (2012), 1297–1309.
27. 27 Wiviott, S.D., White, H.D., Ohman, E.M., et al. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet 382 (2013), 605–613.
28. 28 Wallentin, L., Becker, R.C., Budaj, A., et al., PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009), 1045–1057.
29. 29 Storey, R.F., Oldroyd, K.G., Wilcox, R.G., Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 85 (2001), 401–407.
30. 30 Bhatt, D.L., Stone, G.W., Mahaffey, K.W., et al., for the CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368 (2013), 1303–1313.
31. 31 Bhatt, D.L., Lincoff, A.M., Gibson, C.M., et al., for the CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361 (2009), 2330–2341.
32. 32 Harrington, R.A., Stone, G.W., McNulty, S., et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 361 (2009), 2318–2329.
33. 33 Mega, J.L., Close, S.L., Wiviott, S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360 (2009), 354–362.
34. 34 Karaźniewicz-Łada, M., Danielak, D., Główka, F., Genetic and non-genetic factors affecting the response to clopidogrel therapy. Expert Opin Pharmacother 13 (2012), 663–683.
35. 35 Simon, T., Verstuyft, C., Mary-Krause, M., et al., for the French Registry of Acute ST-Elevation and Non–ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360 (2009), 363–375.
36. 36 Ottervanger, J.P., Armstrong, P., Barnathan, E.S., et al., for the GUSTO IV-ACS Investigators. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV—Acute Coronary Syndrome). Trial. Circulation 107 (2003), 437–442.
37. 37 Giugliano, R.P., White, J.A., Bode, C., et al., for the EARLY ACS Investigators. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 360 (2009), 2176–2190.
38. 38 Stone, G.W., Bertrand, M.E., Moses, J.W., et al., for the ACUITY Investigators. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA 297 (2007), 591–602.
39. 39 Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 (2006), 1464–1476.
40. 40 Yusuf, S., Mehta, S.R., Chrolavicius, S., et al., for the OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295 (2006), 1519–1530.
41. 41 Simoons, M.L., Bobbink, I.W., Boland, J., et al., for the PENTUA Investigators. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol 43 (2004), 2183–2190.
42. 42 Krumholz, H.M., Anderson, J.L., Bachelder, B.L., et al. ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to develop performance measures for ST-elevation and non-ST-elevation myocardial infarction): developed in collaboration with the American Academy of Family Physicians and the American College of Emergency Physicians: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine. J Am Coll Cardiol 52 (2008), 2046–2099.
43. 43 Bonow, R.O., Masoudi, F.A., Rumsfeld, J.S., et al. ACC/AHA classification of care metrics: performance measures and quality metrics: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol 52 (2008), 2113–2117.
44. 44 Smith, S.C. Jr., Benjamin, E.J., Bonow, R.O., et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. J Am Coll Cardiol 58 (2011), 2432–2446.
45. 45 Mukherjee, D., Fang, J., Chetcuti, S., et al. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 109 (2004), 745–749.
46. 46 Nallamothu, B., Fox, K.A., Kennelly, B.M., et al., for the GRACE Investigators. Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events. Heart 93 (2007), 1552–1555.
47. 47 Rosengren, A., Wallentin, L., Gitt, A.K., et al. Sex, age, and clinical presentation of acute coronary syndromes. Eur Heart J 25 (2004), 663–670.
48. 48 Alfredsson, J., Stenestrand, U., Wallentin, L., et al. Gender differences in management and outcome in non-ST-elevation acute coronary syndrome. Heart 93 (2007), 1357–1362.
49. 49 Alexander, K.P., Chen, A.Y., Newby, L.K., et al., for the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Investigators. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation 114 (2006), 1380–1387.
50. 50 Clayton, T.C., Pocock, S.J., Henderson, R.A., et al. Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial. Eur Heart J 25 (2004), 1641–1650.
51. 51 Kim, C., Redberg, R.F., Pavlic, T., et al. A systematic review of gender differences in mortality after coronary artery bypass graft surgery and percutaneous coronary interventions. Clin Cardiol 30 (2007), 491–495.
52. 52 Sidhu, R.B., Brown, J.R., Robb, J.F., et al. Interaction of gender and age on post cardiac catheterization contrast-induced acute kidney injury. Am J Cardiol 102 (2008), 1482–1486.
53. 53 Capodanno, D., Angiolillo, D.J., Antithrombotic therapy in the elderly. J Am Coll Cardiol 56 (2010), 1683–1692.
54. 54 Gurbel, P.A., Ohman, E.M., Jeong, Y.H., et al. Toward a therapeutic window for antiplatelet therapy in the elderly. Eur Heart J 33 (2012), 1187–1189.
55. 55 Buber, J., Goldenberg, I., Kimron, L., et al. One-year outcome following coronary angiography in elderly patients with non-ST elevation myocardial infarction: real-world data from the Acute Coronary Syndromes Israeli Survey (ACSIS). Coron Artery Dis 24 (2013), 102–109.
56. 56 Damman, P., Clayton, T., Wallentin, L., et al. Effects of age on long-term outcomes after a routine invasive or selective invasive strategy in patients presenting with non-ST segment elevation acute coronary syndromes: a collaborative analysis of individual data from the FRISC II-ICTUS-RITA-3 (FIR) trials. Heart 98 (2012), 207–213.
57. 57 Gale, C.P., Cattle, B.A., Woolston, A., et al. Resolving inequalities in care? Reduced mortality in the elderly after acute coronary syndromes. The Myocardial Ischaemia National Audit Project 2003-2010. Eur Heart J 33 (2012), 630–639.
58. 58 Alexander, K.P., Newby, L.K., Cannon, C.P., et al. Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 115 (2007), 2549–2569.
59. 59 Alexander, K.P., Chen, A.Y., Roe, M.T., et al., for the CRUSADE Investigators. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294 (2005), 3108–3116.
60. 60 Farkouh, M.E., Domanski, M., Sleeper, L.A., et al., for the FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 367 (2012), 2375–2384.
61. 61 Franklin, K., Goldberg, R.J., Spencer, F., et al. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med 164 (2004), 1457–1463.
62. 62 NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360 (2009), 1283–1297.
63. 63 Hansen, M.L., Sorensen, R., Clausen, M.T., et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170 (2010), 1433–1441.
64. 64 Dewilde, W.J., Oirbans, T., Verheugt, F.W., et al., for the WOEST Study Investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381 (2013), 1107–1115.
65. 65 Yeh, R.W., Kereiakes, D.J., Steg, P.G., et al., for the DAPT Study Investigators. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol 65 (2015), 2211–2221.
66. 66 Mauri, L., Kereiakes, D.J., Yeh, R.W., et al., for the DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
67. 67 Tricoci, P., Allen, J.M., Kramer, J.M., et al. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA 301 (2009), 831–841.